GlassScriptPhysician profile
Holly Gunn
NPI 1467655431
$34,766.83
in general payments reported to CMS, 2019-2025
33 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,801 · 2021: $2,663 · 2022: $1,567 · 2023: $4,742 · 2024: $5,396 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,657 · Travel and Lodging: $2,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,657.13 |
| Travel and Lodging | $2,626.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $27,976.99 | 2019-2025 | Xeomin |
| Abbvie INC. | $1,713.23 | 2019-2025 | |
| Galderma Laboratories, L.P. | $908.17 | 2019-2025 | Dysport |
| Allergan, INC. | $580.35 | 2019-2022 | |
| Lumenis Be INC | $461.46 | 2024-2025 | M22 |
| Janssen Biotech, INC. | $373.11 | 2021-2024 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $294.06 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $259.26 | 2019-2025 | Blu-U, Odomzo |
| Strata Skin Sciences, INC. | $233.67 | 2022-2025 | Xtrac |
| Pfizer INC. | $208.10 | 2019-2025 | |
| Dermavant Sciences, INC. | $200.78 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $162.28 | 2025 | Daxxify |
| Amgen INC. | $159.31 | 2020-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $140.04 | 2019-2023 | Arazlo, Jublia |
| Leo Pharma INC. | $139.93 | 2019-2023 | Adbry |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $123.78 | 2019-2024 | Bimzelx |
| Sientra, INC. | $108.98 | 2021 | |
| Dermira, INC. | $98.59 | 2019-2020 | |
| Incyte Corporation | $96.14 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $79.82 | 2020-2025 | Ebglyss |
| Vyne Pharmaceuticals INC. | $67.80 | 2020-2021 | |
| Genzyme Corporation | $60.28 | 2019-2020 | |
| Aclaris Therapeutics, INC. | $58.50 | 2019 | |
| Dusa Pharmaceuticals, INC. | $50.85 | 2019 | |
| Epi Health, LLC | $49.20 | 2019-2021 | |
| Almirall LLC | $42.54 | 2019 | |
| Prugen, INC. Pharmaceuticals | $24.02 | 2020 | |
| Celgene Corporation | $23.68 | 2019 | |
| Arcutis Biotherapeutics, INC. | $19.51 | 2023 | |
| Verrica Pharmaceuticals INC. | $19.16 | 2024 | Ycanth |
| Therapeuticsmd, INC. | $12.44 | 2019 | |
| Mission Pharmacal Company | $12.03 | 2019 | |
| Kerecis Limited | $8.77 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Gunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.